Benjamin Martin, MD
Urology · Gahanna, OHNPI 1609893221
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,976 of the $204,551 with a category attached, or 62.1%. 48 manufacturers reported payments, led by Bayer at 30.4% of the total. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 557 payments — averaging $367.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$62K
- Dendreon Pharmaceuticals LLC$50K
- Johnson & Johnson$32K
- Myovant Sciences Inc.$14K
- Astellas Pharma US Inc$14K
- Ferring Pharmaceuticals Inc.$7K
- plus $25K from 42 others
Across 160 payments — averaging $5833.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$662K
- Bayer$123K
- Dendreon Pharmaceuticals LLC$102K
- Sumitomo Pharma America, Inc.$33K
- Ferring Pharmaceuticals AS$11K
- AstraZeneca$2K
- plus $74 from 1 others
What the payments were for
- Consulting fees$46,29423%
- Speaking & faculty fees$126,97662%
- Travel & lodging$16,5968%
- Food & beverage$14,3357%
- Education$3500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$204,551 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 183 | $2,297,612 |
| XtandiEnzalutamide | 135 | $1,437,039 |
| Abiraterone Acetate | 627 | $1,174,589 |
| OrgovyxRelugolix | 330 | $888,373 |
| ErleadaApalutamide | 62 | $619,510 |
| LynparzaOlaparib | 19 | $299,081 |
| YonsaAbiraterone Acet,submicronized | 13 | $130,697 |
| GemtesaVibegron | 34 | $23,369 |
| MyrbetriqMirabegron | 25 | $16,235 |
| Tamsulosin Hcl | 199 | $4,131 |
| Potassium Citrate ErPotassium Citrate | 28 | $3,950 |
| Finasteride | 234 | $3,345 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 154 | $3,100 |
| Methenamine Hippurate | 28 | $2,266 |
| Prednisone | 650 | $2,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $62,114 | $2,297,612183 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $14,071 | $1,453,274160 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $53 | $1,174,589627 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $421 | $911,742364 claims |
| Johnson & JohnsonErleada | $31,883 | $619,51062 claims |
| AstraZenecaLynparza | $3,322 | $299,08119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Gahanna
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
- Raymond RackleyCleveland$152K
- Petar BajicCleveland$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.